Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
Trends in Low-Value Cancer Care During the COVID-19 Pandemic
Among adults with newly diagnosed cancer, rates of low-value cancer services persisted throughout the COVID-19 pandemic in areas ranging from peridiagnosis imaging to end-of-life care.
Read More
Dr Mila Felder Discusses Peer-to-Peer Support in Health Care Organizations
April 4th 2024Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health, discusses the impact of peer support groups within a health care organization and its patients.
Watch
2024 COA Community Oncology Conference Preview With Dr Emily Touloukian
April 1st 2024With the 2024 Community Oncology Conference, from the Community Oncology Alliance (COA), set to kick off this week in Orlando, Florida, The American Journal of Managed Care® spoke with Emily Touloukian, DO, COA board member and 1 of 6 cochairs for this year’s meeting, on highlights from the packed agenda and the power of advocacy.
Watch
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More
Navigating the Mental Health Challenges of Cancer Diagnosis, Treatment, and Survivorship
March 12th 2024Stress has potential links to worse outcomes in cancer, such as decreased quality of life and greater risks of disease progression and metastasis. There is a complex mix of emotions patients with cancer experience.
Read More
QCCA, NCCA Merge to Form ONCare Among Independent Oncology Practices
February 29th 2024ONCare Alliance will be led by 2 of the leading women in community oncology, cochairs Barbara McAneny, MD, of the New Mexico Cancer Center, and Sibel Blau, MD, of Northwest Medical Specialties, PLLC, of Puyallup, Washington.
Read More
What Are the Steps to Quality Improvement in Cancer Care?
February 29th 2024Quality Improvement (QI) projects require a series of distinct steps and timely data collection that will allow clinics to see if changes are yielding results, a consultant told attendees at a preconference workshop at ACCC.
Read More
What We’re Reading: Alabama IVF Ruling Impacts; Administrative Task Fees; Nursing Shortage Response
February 26th 2024Patients with cancer express shock and anxiety over the recent ruling by the Alabama Supreme Court regarding frozen embryos; doctors are beginning to charge fees for administrative tasks; some universities are implementing accelerated nursing programs to help with the shortage.
Read More
Getting to Know Dr Chandler Cortina, Breast Surgical Oncologist
February 9th 2024Chandler Cortina, MD, MS, FSSO, FACS, is assistant professor of surgery and breast surgical oncologist at Froedtert & the Medical College of Wisconsin. His current research focuses on breast cancer risk not only in general but also among transgender and gender-diverse populations.
Read More
COA's Dr Miriam Atkins: PBMs, HR 5526, and Marketplace Strategy
February 7th 2024Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance, discusses the impact of pharmacy benefit managers (PBMs) on health care costs and offers potential ways to remedy certain CMS decisions that negatively affect oncologists and their patients.
Watch
Priority Review Granted for Trastuzumab Deruxtecan; Would Be First Tumor-Agnostic ADC
January 30th 2024A tumor-agnostic approval would be a significant development in the advance of antibody-drug conjugates (ADCs), which are designed to deliver a potent, cancer-fighting payload into a tumor while sparing nearby tissues.
Read More
Dr Lucy Langer: How UnitedHealthcare Is Enhancing Oncology Pathway Adherence and Promoting Equity
January 28th 2024UnitedHealthcare's oncology payment mode initially involved a pay-for-performance program based on pathways adherence, and will be transitioning in 2024 to a broader system with graded quartiles to incentivize greater participation and pathway adherence.
Watch
Dr Samyukta Mullangi Talks Cost Reductions, Scalability of Thyme Care's Navigation Program
January 22nd 2024The Thyme Care virtual navigation program demonstrated a $594 reduction in total costs per member per month for navigated cancer patients compared with a control group, emphasizing the scalability of the independent virtual navigation model across various contracts, with opportunities to adapt to different populations and needs in the evolving landscape of value-based care arrangements.
Read More
First-Line Tiragolumab With Atezolizumab Plus Chemo Improves PFS, OS in Patients With ESCC
January 16th 2024Treatment with both PD-1 and TIGIT immunotherapy alongside chemotherapy demonstrated improved progression-free (PFS) and overall survival (OS) compared with chemotherapy alone in patients with esophageal squamous cell carcinoma (ESCC).
Read More
Dr Kirollos Hanna Talks Chemotherapy Shortage Challenges and Solutions
January 15th 2024Especially during shortages, Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, director of pharmacy services at Minnesota Oncology, says practices should carve out areas where going to a different therapeutic approach isn't considered off-pathway.
Read More